Method for early postoperative treatment of chronic rhinosinusitis
SUBSTANCE: invention represents a method for early postoperative treatment of chronic rhinosinusitis involves a pre-anemisation of a nasal mucosa with an adrenalin solution, a decrustation involves by the fact that the decrustation is followed by administering the preparation 'Argogel' 1.0 ml 2 times a day for 10 minutes throughout 2 weeks.
EFFECT: reducing the length of treatment by fast elimination of the clinical manifestations of the inflammation, as well as maintaining a stable remission, expanding the range of drugs applicable in otorhinolaryngology.
4 dwg, 2 ex
The invention relates to medicine, namely to otorhinolaryngology, and can be used for the treatment of patients with chronic rhinosinusitis in the early postoperative period.
The known method of complex treatment of chronic sinusitis, including the rehabilitation of the maxillary sinuses with a solution of furatsillin them by pre-catheterization through artificially imposed fistula with subsequent introduction into the cavities of 0.5% solution of digidrokvercetina and led phototherapy (see patent No. 2308992, IPC7A61N 5/06, A61K 38/56, publ. 27.10.2007).
The disadvantages of analog is the need to use additional expensive equipment led light therapy to achieve the desired result.
The closest in technical essence and the achieved result is a method of treatment of patients with chronic rhinosinusitis in the early postoperative period, including a preliminary anemizatsii mucosa of the nasal cavity with a solution of adrenaline, removal of crusts (see Shcheglov, A. N. Endoscopic surgery of maxillary sinuses through minimal access. The dissertation on competition of a scientific degree of candidate of medical Sciences, Moscow, 2011).
The disadvantages of this method is the preservation of the clinical manifestations of inflammation is detachable from the cavity h�sa, the presence of the wound surface in a month, and three months later cytological examination of the mucosa of the nasal cavity indicates an inflammatory process.
The objective of the proposed technical solution is the reduction of terms of treatment due to the rapid elimination of clinical manifestations of inflammation, preservation of stable remission, expanding the range of drugs used in otolaryngology.
The solution of a technical problem is achieved in that in the method of treating chronic rhinosinusitis in the early postoperative period, including a preliminary anemizatsii mucosa of the nasal cavity with a solution of adrenaline, removal of crusts, according to the invention in the nasal cavity after removal of the crusts administered drug "Argogel" by 1.0 ml 2 times daily for 1 0 minutes for 2 weeks.
This method will allow to reduce terms of treatment due to the rapid elimination of clinical manifestations of inflammation and also to maintain a stable remission, to expand the range of medicinal drugs used in otolaryngology.
The invention is illustrated by photographs of cytological examination of smears of fingerprints by the mucous membrane of the nasal cavity, where Fig.1 shows a completely polymorphonuclear leukocytes isolated cellular elements slabomineralizovannaja on day 2 after removal of the swab�in, Fig.2 - a significant number of neutrophils, cellular elements without atypia and slabomineralizovannaja 2 week postoperative treatment, Fig.3 - isolated polymorphonuclear leukocytes intact cells - a month after the operation, Fig.4 - clean background after 3 months.
Argogel represents a highly dispersive (cluster) silver in the hydrophilic matrix of the gel of polyethylene oxide. The gel forms on the surface of the wound air - and moisture-permeable coating, provides prolonged action of nanosilver, absorbs exudate, i.e. has a drying effect. The drug has a broad spectrum antimicrobial action against gram-positive and gram-negative, aerobic and anaerobic, spore-forming and asporogenous bacteria in the form of monocultures and microbial associations, including antibiotikoustoichivosti of hospital strains. Argogel exhibits a high virucidal and fungicidal activity, has a pronounced anti-inflammatory action, stimulates reparative processes.
A method of treating chronic rhinosinusitis in the early postoperative period was carried out as follows.
Patients have a toilet of the nasal cavity - anemizatsii with adrenaline and removing crusts - and the subsequent introduction of the common nasal passage of the drug "Argogel�" according to the following scheme: 1.0 ml in each half of the nasal cavity for 10 minutes 2 times a day. The course of treatment was 2 weeks.
The method was tested on 50 patients with chronic rhinosinusitis in history at the age from 25 to 70 years, undergoing two days ago, bilateral endoscopic hyporthyroidism or bilateral radical surgery on the maxillary sinus and bilateral polipotomy nose with a partial opening of the cells of the ethmoid labyrinth. The assessment of the dynamics of clinical manifestations of the disease was performed for 10 days in a month and 3 months after surgery. Account of subjective symptoms on a 10-point scale: function of nasal breathing, the amount of discharge from the nasal cavity, the olfactory function. The course of wound healing was evaluated visually with daily rhinoscopy - hyperemia, edema of the mucosa of the nasal cavity, the number and nature of the discharge from the nasal cavity; and cytological examination of smears-prints from the mucous membrane of the nasal cavity. Smears were taken with a cotton tempfrom soaked in sterile isotonic, in the area of the middle turbinate. Rotational movements without pressure was applied brush strokes in a grease-free glass slides, then dried, fixed and stained by Romanovsky-Giemsa. Microscopy was carried out under immersion with increasing (CA. 7, vol. 90). It was found that the amount of discharge within 2 weeks noticeable�about decreased nasal breathing recover quickly, which was confirmed by cytological examination of smears of fingerprints by the mucous membrane of the nasal cavity (see Fig. 1, 2, 3, 4).
Example 1: a Patient was admitted to the surgical Department of the clinical hospital 3 22.08.11 with a diagnosis of Bilateral chronic polypoid maxillary sinusitis, ethmoiditis. The objective at the time of admission: the mucosa of the nasal cavity pink, wet nose passages are rendered polypoid of education emanating from the cells of the ethmoid labyrinth and from under the middle turbinate. Other ENT-organs without pathology. 23.08.11 produced bilateral endoscopic haymore, ethmoidectomy. The following day produced the removal of tampons. With 25.08.11 the patient was carried out the toilet of the nasal cavity - anemizatsii with adrenaline and removing crusts - and the subsequent introduction of the common nasal passage of the drug "Argogel" according to the following scheme: 1.0 ml in each half of the nasal cavity for 10 minutes 2 times a day. The course of treatment was 14 days.
From the fifth day of treatment the amount of discharge from the nasal cavity decreased significantly and by the end of the second week stopped. The first signs of epithelialization erosive surface appeared with 7 days of starting treatment. Complete epithelialization of the wound surface was observed after 2 weeks of treatment. Long-term results - at 1, 3, 6 months showed persistent remission, i.e. �otsutstvie selections and complete epithelization of the wound surface.
Example 2: Patient V. was admitted to the surgical Department CB # 3 15.11.11 with a diagnosis of Bilateral chronic polypoid maxillary sinusitis, ethmoiditis. The objective at the time of admission: the mucosa of the nasal cavity pink, wet nose passages are rendered polypoid of education emanating from the cells of the ethmoid labyrinth and from under the middle turbinate. Other ENT-organs without pathology. 16.11.11 produced bilateral endoscopic haymore, ethmoidectomy. The following day produced the removal of tampons. With 25.08.11 the patient was carried out the toilet of the nasal cavity - anemizatsii with adrenaline and removing crusts - and the subsequent introduction of the common nasal passage of the drug "Argogel" according to the following scheme: 1.0 ml in each half of the nasal cavity for 10 minutes 2 times a day. The course of treatment was 14 days.
From the fifth day of treatment the amount of discharge from the nasal cavity decreased significantly and by the end of the second week stopped. The first signs of epithelialization erosive surface appeared with 10 days of starting treatment. Complete epithelialization of the wound surface was observed after 2.5 weeks of treatment. Long-term results - at 1, 3, 6 months showed persistent remission, i.e. the absence of discharge and complete epithelization of the wound surface.
Using the proposed method of treatment of chronic sinusitis in the early posleoperatsi�nom period will allow for comparison with the prototype to reduce treatment time due to the rapid elimination of clinical manifestations of inflammation, and also keep stable remission, to expand the range of medicinal drugs used in otolaryngology.
A method of treating chronic rhinosinusitis in the early postoperative period, including a preliminary anemizatsii mucosa of the nasal cavity with a solution of adrenaline, removal of crusts, characterized in that in the nasal cavity after removal of the crusts administered drug "Argogel" by 1.0 ml 2 times a day for 10 minutes for 2 weeks.
SUBSTANCE: increase in biocidal and immunobiological action due to the use of distilled water ionised with silver ions and adding into the composition of succinic, ascorbic, citric acid and aethonium.
EFFECT: increase in biocidal immunobiological properties of the antiseptic-stimulant of Dorogov ASD-2F.
6 ex, 1 tbl
SUBSTANCE: two-duct drain tube is intraoperatively inserted into a residual cavity. The tube is delivered onto an anterior abdominal wall. The cyst cavity is irrigated with 0.05% chlorhexidine every day from the second postoperative day that is followed by administering the preparation of 10% povidone iodine with the drain tube pinched for 3-5 minutes. The procedure is performed until the cyst cavity is eliminated completely.
EFFECT: method provides the reliable treatment of the residual cyst cavity following marsupialisation and open echinococcectomy, as well as prevents the postoperative complications by achieving the aseptic inflammation of the inner surface of the fibrous capsule surface followed by the cyst cavity obliteration.
2 dwg, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a new hydrate of 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol hydrochloride salt in the crystalline form with the characteristics below. The hydrate can be used for producing a drug or for treating or preventing a transplanted organ or tissue rejection, or autoimmune diseases in a therapeutically effective amount. The above hydrate is characterised by an X-ray powder diffractogram having peaks at approximately 2.9, 17.2, 30.6, 28.2, 24.4, 8.6 and 25.9 degrees 2-Theta with a limit of error of ±0.2 degrees for each value of 2θ, having a purity of 90% or more, and containing 5.2 to 5.9% of water.
EFFECT: invention also characterises a pharmaceutical composition with using the above hydrate.
4 cl, 4 dwg, 8 tbl, 14 ex
SUBSTANCE: invention can be used for the local treatment of trophic ulcers, infected and persistent septic wounds, degrees I-II-IIIA burns, traumatic skin injuries, pyoinflammatory skin diseases, bed sores, etc. The invention refers to a preparation, which contains a streptocide powder 1-2.5 g, Ichthyol ointment 7-10 g and castol oil 87.5-92 ml.
EFFECT: reducing the length of treatment up to 14 days with no side effects.
SUBSTANCE: invention relates to medicine, namely to veterinary and veterinary obstetrics, and can be applied for the treatment of clinical mastitis in cows. For this purpose after evening milking for 4 days, parts of the udder with signs of mastitis are influenced with an alternating magnetic field from the magnetic-therapeutic apparatus AMnp-02 "Solnyshko". The duration of exposure constitutes 10 minutes. Mastoxidine, heated to 40°C, in a dose of 20 ml three days successively, is additionally intracisternally introduced for 3 days running.
EFFECT: method ensures an increase of the treatment efficiency due to the enforcement of mastoxidine action at deep cellular and intra-cellular levels with the acceleration of its penetration in tissues.
1 dwg, 2 tbl, 2 ex
SUBSTANCE: therapeutic agent contains hypromellose, boric acid and a consistency base; it additionally contains anesthesin or lidocaine as an analgesic in an amount of 0.00001-0.5 g.
EFFECT: fixing a lubricating agent on the catheter enabling preventing mucosal injuries accompanying a drainage procedure, and eliminating side effects.
3 cl, 6 ex
FIELD: veterinary medicine.
SUBSTANCE: preparation for treatment of infected wounds in the toe region of animals, containing dimethyl sulphoxide, methyl cellulose, additionally comprises tylosin tartrate, sulphadimine, trimethoprim in the following ratio of components, wt %: tylosin tartrate - 2-3, sulphadimine - 4-5, trimethoprim - 1-1.5, dimethyl sulphoxide - 10-15, methylcellulose - 3.0-3.5, water - the rest. The claimed method comprises applying the claimed preparation without preliminary wound cleaning. The preparation is applied to the wound with the layer thickness of 2-3 mm, without application of soft dressing. The treated animals are kept for 2-3 hours on the dry surface.
EFFECT: use of claimed group of inventions increases the efficiency of treatment.
4 cl, 7 tbl, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition for treating gastroduodenal ulcer in the form of tablets, capsules or gel, containing therapeutic agents and a consistency base applicable for each dosage, wherein the therapeutic agents are as follows: recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; antiseptics; amino acids specified in a group: arginine, histidine, lysine, cysteine, methionine, glutamic acid; and antioxidants specified in a group: beta-carotene, vitamin C, vitamin E.
EFFECT: invention has the integrated body effect promoting faster healing of the mucosal defect accompanying the aggravated gastroduodenal ulcer and preventing recurrences, including by the eradication effect.
6 cl, 5 ex
FIELD: veterinary medicine.
SUBSTANCE: pharmaceutical composition in the form of ointments for treatment of mastitis in cows comprises n-tetradecyltributylphosphonium bromide as active ingredient and petrolatum as an excipient at the ratio of 1:2000.
EFFECT: invention provides a pharmaceutical composition in the form of an ointment, which is new in mechanism of action, effective when applied topically at low therapeutic concentration.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition in the form of tablets for oromucosal administration in treating infectious-inflammatory oropharyngeal diseases. The composition contains recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; amino acid specified in a group: arginine, histidine, glycine, glutathione, lysine, methionine, cysteine; an antiseptic, a preserving agent, flavours specified in a group: tea tree oil, eucalyptus leaf oil, mint leaf oil and a consistence base.
EFFECT: invention makes the composition applicable in fragile and frequently ill patients for reducing a disease recurrence.
7 cl, 1 ex
SUBSTANCE: composition for nasal application, containing active and additive ingredients, wherein the active ingredients are presented by sea salt and α-glutamyl-tryptophan in the following ratio of the active ingredients (wt %): sea salt 95.00-98.00; alpha-glutamyl-tryptophan 2.00-5.00. The group of inventions also refers to a therapeutic agent, a method, using and a medical device for preventing or treating upper airway diseases.
EFFECT: group of inventions promotes slime evacuation, reduces infected nasal discharge and relieves swollen mucosa, softens and removes crusts and enhances body defences, as well as normalises the barrier function of nasal mucosa epithelium, improves nasal breathing and causes moistening and anti-inflammatory action.
18 cl, 3 tbl, 1 ex
SUBSTANCE: method involves an endoural ultrasonic exposure covering the middle ear tissues with the use of a therapeutic agent used as a medium; the medium is presented with solution of thiamphenicol glycinate acetylcisteinate. The ultrasonic exposure is generated at oscillating amplitude 40 mcm, frequency 26.5 kHz and length 15 sec with the course of 7 procedures performed daily.
EFFECT: method enables providing the higher therapeutic effectiveness in secretory otitis media by using the declared parameters of the ultrasonic exposure enabling to avoid injuries of the middle ear tissues, as well as providing higher bioavailability of the preparation possessing the wide spectrum of antibacterial preparation, antiadhesive, antioxidant, anti-inflammatory action.
SUBSTANCE: invention relates to 2,5 substituted arylsulphonamides of formula (Ia) or to their pharmaceutically acceptable salts, solvates, hydrates, stereoisomers or tautomers, where X represents S, SO or SO2; Y and Z represents (i) Y represents NR5; and Z represents =O, CO2R6 or C1-6alkyl; or (ii) Y represents CH2, CHF, CHCH3, O, S or SO2; and Z represents hydrogen or C1-6alkyl; R1 and R2 each independently represents halogen, C1-6alkyl or C1-6 halogenalkyl; R3 represents CN or NO2; R4 represents hydrogen or C1-6alkyl; R5 represents hydrogen or C1-6alkyl; and R6 represents hydrogen or C1-6alkyl. Invention also relates to compounds of formula (I) and (II), values of radicals of which are given in the invention formula, specific compounds, pharmaceutical composition based on compound of formula
method of modulating CCR3 activity.
EFFECT: obtained are novel compounds, possessing useful biological properties.
18 cl, 1 tbl, 3 ex
SUBSTANCE: area of inflammation is exposed to ultrasound generated by the Sonoca 185 apparatus. The exposure power gradually grows within the range of 20 to 40-80 W depending on age. The palatal tonsils are alternately sanitised with octenisept dissolved in 0.9% sodium chloride in a ratio 1:8 with an octenisept flow rate gradually increasing within the range from 20 to 180 ml/s, an exposure time of 2-5 seconds for 3-5 minutes. The therapeutic course is 8-10 sessions, either daily or every second day.
EFFECT: method involves the integrated effect of ultrasound and antiseptic on the oropharyngeal mucosa in the developed regimen that enables providing the higher therapeutic effectiveness, including that in children suffering from chronic tonsillitis, reducing a probability of complications, improving an acceptability of presented therapy.
SUBSTANCE: invention relates to an agent for preventing and/or treating an allergic disease selected from pollinosis, allergic rhinitis, allergic conjunctivitis, atopic dermatitis and asthma, which is a low-molecular polysulphated hyaluronic acid derivative.
EFFECT: obtaining a low-molecular polysulphated hyaluronic acid derivative.
15 cl, 103 dwg, 17 tbl, 55 ex
SUBSTANCE: invention relates to compounds of general formula or , where Ar1 represents phenyl group, optionally substituted with one or several identical or non-identical halogen atoms; R1 represents hydrogen atom; R4, R5, R6a, R6b represent hydrogen atoms; Y, Z independently represent linear C1-4 alkylene group, optionally substituted with one linear C1-4 alkyl group; Ar2 stands for condensed with benzene 5-membered heterocyclic ring, containing one nitrogen atom and one sulphur atom, substituted with one linear C1-4 alkyl group, or derivative of 5- or 6-membered heterocyclic ring, containing one nitrogen atom and one sulphur atom, condensed with heteroaromatic 6-memebered ring, containing one or two nitrogen atoms, substituted with one linear C1-4 alkyl group, linear C1-4 alkoxygroup or group -NR7R8, where R7 and R8 independently stand for hydrogen atom, linear or branched C1-4 alkyl group, or R7 and R8 together with nitrogen atom form group of general formula , where R2, R3 represent linear C1-4 alkyl groups, A stands for group -CHR12, oxygen atom or group -NR9, where R12 and R9 stand for hydrogen atom or linear C1-4 alkyl group, m has value 1 or 2, n has value 1 or 2, o has value 0 or 1, p has value 0 or 1, Q stands for group -O-, group -N--H or group -N--CO-R10, where R10 stands for linear C1-4 alkyl group or -NH-R11 group, where R11 represents linear C1-4 alkyl group; and to their salts. Invention also relates to methods of obtaining therein and to based on them pharmaceutical composition, possessing antagonistic activity with respect to receptor CCR3.
EFFECT: obtained are novel compounds and based on them pharmaceutical compositions, which can be applied in medicine for obtaining medication, intended for treating asthma, allergic rhinitis, atopic dermatitis, eczema, inflammatory intestinal diseases, ulcerous colitis, Crohn's disease, allergic conjunctivitis, multiple sclerosis or HIV-infection and AIDS-associated diseases.
14 cl, 3 tbl, 26 ex
SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology, and may be used for the preoperative preparation of the patients suffering a perforated nasal septum. Intranasal silicone splints are placed 10 days before the operation. The splint is incised from one side within a perforation border. A 30° endoscope is used to assist a 7-day daily nasal perforation rinsing with chlorhexidine. A suction unit is used to evacuate mucosal secretion; synthomycin ointment is introduced through the incision in the silicone splint to the perforation region. The nasal cavity is irrigated daily with antiseptic and vasoconstrictive preparations. On the 7th day, the intranasal splints are removed.
EFFECT: method enables relieving the mucosal inflammation within the perforation, promotes the prolonged drug retention in the introduction place, ensures avoiding an overlay of a secondary infection, improves the functional state of ciliated epithelium.
SUBSTANCE: throat tonsil is treated with octenisept dissolved in 0.9% saline in ratio 1:10. The treatment involves right and left nostrils alternately for 3 seconds 30-40 times for 6-10 minutes. The treatment is combined with the ultrasonic exposure generated by Sonoka 180 at frequency 20-40 kHz. The therapeutic course is 6-7 sessions, either daily or every second day.
EFFECT: fast nasopharyngeal sanitation, reduced local inflammatory response, improved nonspecific resistance of the throat tonsil at enhancing the humoral immunity factors that in turn improves the quality of life of these patients.
SUBSTANCE: invention refers to medicine, particularly to otorhinolaryngology, and may be used for treating acute and chronic rhinosinusitis is adults and children. A nasal mucosa is anematised with 0.1% adrenaline hydrochloride or vasoconstrictor drops. A nasopharynx is sealed with a soft palate; air and nasal contents are aspirated from one nostril to be washed by drug injection into an opposite nostril. Herewith, 20-30 minutes before the beginning of the procedure, Sinuforte nasal spray is introduced into the nasal cavity to induce a reflectory hypersecrection in the paranasal mucosa. The patient is placed in a sitting or reclining position with a head lag so that a posterior wall of the nasopharynx is at an angle of 45° to a horizontal plane of the head. A medical electric suction machine with an olive adjuster to be rotated clockwise is placed directly on an area of a osteomeatal complex directly, namely on a medium nasal passage.
EFFECT: method requires no special equipment and apparatuses; it is painless, provides the high therapeutic effect ensured by sanitation of all the sinuses.
7 ex, 6 dwg
SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology, and may be used in conducting the antiviral therapy in treating antiviral and hyperplastic nasopharyngeal diseases in children. That is ensured by prescribing cyclopheron in the period of acute clinical manifestations in a clinically effective daily doses prescribed considering patient's weight and age in the five- or ten-day therapeutic course in a combination with the local administration of 20% aqueous sulphacyl sodium 2-3 drops in both nostrils with patient's head lag 3 times a day in the ten-day therapeutic course. Cyclopheron is prescribed in rarely ill patients suffering ARVIs in the five-day therapeutic courses. In recurrently ill patients and in the setting of hyperplastic nasopharyngeal conditions, in chronic nasopharyngitis, chronic adenoiditis and pharyngeal lymphoid tissue ring hyperplasia, the patient undergoes the ten-day therapeutic course in each aggravation of clinical manifestations to reduce the rate of acute clinical manifestation and stable clinical remission. Local sanitation of the inflammation centre with sulphacyl sodium in all cases is performed within the ten-day therapeutic courses.
EFFECT: invention enables reducing the length and rate of the aggravations of inflammatory and hyperplastic nasopharyngeal diseases in children.
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to antiseptic compositions and applicable for disinfection of surfaces, such as body surfaces, and for treatment of infection-related conditions. As active ingredients, an antiseptic composition contains menthol and silver ions, and a pharmaceutically acceptable carrier. The silver ion concentration in the composition makes from 0.25 mM to 0.6 mM, whereas the menthol concentration makes from 0.64 mM to 6.4 mM. What is also presented is an antiseptic kit containing the above composition and a packaging material. Other embodiments involve a method for producing the above antiseptic composition, a method for reducing the silver ion concentration in the antiseptic composition and a method for increasing the antiseptic activity of the above composition.
EFFECT: using the group of inventions provides producing the antiseptic composition that is ensured by the synergetic effect of menthol and silver ions in the used concentrations in relation to various bacteria.
16 cl, 5 tbl, 6 ex, 4 dwg